DASP is a collaboration of the IDS and the Centers for Disease Control and Prevention (CDC) to improve the sensitivity, specificity and comparability of the measurement of autoantibodies associated with type 1diabetes. DASP is built upon the foundation of previous IDS Workshops that demonstrated marked variability between laboratories in the sensitivity and specificity of assays for autoantibodies to GAD65, IA-2A, and insulin.
The first DASP Proficiency Testing (PT) evaluation in the fall of 2000 showed that radiobinding assays for GADA and IA-2A generally achieve high sensitivity and specificity, and that inter-laboratory concordance is good when samples are ranked, or if results are expressed in common units based on the WHO reference reagent. It did however indicate that that problems persist in the measurement of autoantibodies to insulin. Some IAA microassays have high levels of sensitivity and specificity with good concordance among laboratories, but the sensitivity of assays in most laboratories is low.